

Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial

by Shu Chen, Weiwei Qin, Xiaohong Lu, Li Liu, Yinsuo Zheng, Xinhua Lu, Xiaohui Wang, Xiaojuan Zhang, Sha Gong, Suhua Wei, Huiyun Zhang, Hanru Ding, Ranjbarha Seifollah, Jing Li, Haitao Zhang, Di Wu, Olubukola Abiona, Pengcheng He, Rong Zhang, David Wald, and Huaiyu Wang

Received: May 27, 2024.

Accepted: October 30, 2024.

Citation: Shu Chen, Weiwei Qin, Xiaohong Lu, Li Liu, Yinsuo Zheng, Xinhua Lu, Xiaohui Wang, Xiaojuan Zhang, Sha Gong, Suhua Wei, Huiyun Zhang, Hanru Ding, Ranjbarha Seifollah, Jing Li, Haitao Zhang, Di Wu, Olubukola Abiona, Pengcheng He, Rong Zhang, David Wald, and Huaiyu Wang. Arsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial.

Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.285905 [Epub ahead of print]

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.

E-publishing of this PDF file has been approved by the authors.

After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.

All legal disclaimers that apply to the journal also pertain to this production process.

Arsenic trioxide *versus* Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial

Shu Chen,¹ Weiwei Qin,² Xiaohong Lu,³ Li Liu,² Yinsuo Zheng,⁴ Xinhua Lu,¹ Xiaohui Wang,¹ Xiaojuan Zhang,¹ Sha Gong,¹ Suhua Wei,¹ Huiyun Zhang,⁵ Hanru Ding,¹ Ranjbarha Seifollah,¹ Jing Li,¹ Haitao Zhang,¹ Di Wu,¹ Olubukola Abiona,⁶ Pengcheng He,¹ Rong Zhang,⁷ David Wald,⁶ and Huaiyu Wang^{1*}

¹Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China;

²Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi Province, China;

³Department of Rheumatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China;

⁴Department of Hematology, Baoji Central Hospital, Baoji, Shaanxi Province, China;

⁵Department of Oncology, Qinghai Provincial People's Hospital, Xining, Qinghai Province, China;

⁶Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; and

⁷Department of Hematology, Xi'an Gaoxin Hospital, Xi'an, Shaanxi Province, China.

Running heads: A randomized trial of RIF *versus* ATO for APL

*** Corresponding author:**

Huai-Yu Wang, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, Shaanxi, China.

Email: whymed@126.com. Phone: +86 18991232410.

Authors' contributions:

H.-Y.W. designed the study; S.C. analyzed the data; L.L., Xiao-Hong Lu, W.-W.Q. wrote the manuscript; Y.-S.Z., P.-C.H., S.-H.W., R.Z., X.-H.W., H.-Y.Z., G.S., H.-R.D. and Xin-Hua Lu contributed to data collection; Di Wu, J.L., H.-T.Z., X.-J.Z. performed the cytogenetic analysis; O.A., R.S., and David Wald reviewed the manuscript and modified the content; and all authors contributed to the final draft.

Data sharing statement: The data that support the findings of this study are available on request from the corresponding author upon reasonable request.

Trial registration: ClinicalTrials.gov identifier: NCT02899169.

Funding: This study was funded by the First Affiliated Hospital of Xi'an Jiaotong University. (Grant No. XJTU1AF2016LSL-017)

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Prior presentation: Presented in abstract form at the 64th annual meeting of the American Society of Hematology, Louisiana, 9 December 2022.

Abstract

Realgar-Indigo Naturalis Formula (RIF) is an oral form of arsenic that is effective against acute promyelocytic leukemia (APL). This multicenter, randomized, controlled trial compared the efficacy of all-trans retinoic acid (ATRA) plus RIF with ATRA plus arsenic trioxide (ATO) in a simplified regimen for non-high-risk APL. Following induction therapy with ATRA and ATO, participants were randomly assigned to receive either ATRA plus ATO or ATRA plus RIF both in a 2-week on 2-week off schedule for consolidation therapy. Once achieving molecular complete remission, the regimen was administered for a total of 6 cycles. All of 108 eligible patients achieved hematological complete remission after induction therapy. The median follow-up time was 29 months. The primary endpoint of two-year disease-free survival was 97% in the ATRA-RIF arm and 98% in the ATRA-ATO arm, respectively. (The ATRA-RIF arm was found to be non-inferior to the ATRA-ATO arm, ($P < .01$), with a percentage difference of -1% (95%CI, -4.8 to 6.9). No deaths have been observed. Most adverse events were moderate. This study confirms the noninferiority of RIF to ATO for non-high-risk APL, while also offering a more favorable regimen schedule for post-remission therapy. (*ClinicalTrials.gov. Identifier: as NCT02899169*).

Introduction

The pivotal study of acute promyelocytic leukemia 0406 (APL0406) demonstrated that the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) resulted in improved survival and quality of life compared to using ATRA plus chemotherapy in non-high-risk APL^{1,2}. In the era of arsenic-based therapy, oral arsenic offers the advantage of reduced medical costs and a shorter hospital stay³. Realgar-Indigo Naturalis Formula (RIF), a traditional Chinese medicine, has been shown to be effective against APL and is available in China⁴⁻⁷. RIF is an oral arsenic compound consisting of realgar (contains approximately 90% As₄S₄), *indigo naturalis*, *salvia miltiorrhiza*, and *radix pseudostellariae* (adjuvant components to assist the effects of realgar)^{6,8}. Furthermore, a recent long-term clinical trial has confirmed the efficacy of RIF in a chemotherapy-containing regimen for pediatric patients⁹.

APL patients require prolonged hospital stays for intravenous ATO treatment. A completely oral combination of ATRA and RIF presents a prominent advantage in China, where there is a large population and limited medical resources. Although oral ATO was available in Hong Kong, the three-year event-free survival rate was only 83.7% in an oral ATO containing maintenance therapy¹⁰. RIF remained the most prevalent oral arsenic agent in China¹¹.

Previous studies of APL used an alternating administration of ATO for 4 weeks on and 4 weeks off, and ATRA for 2 weeks on and 2 weeks off as the post-remission regimen^{1,12}. However, this approach may be inconvenient for clinical management and confusing for patients due to the different intervals of the two drugs. In a prior study, we applied a simplified regimen in which both drugs were administered on the same schedule of 2 weeks on and 2 weeks off. The safety and efficacy of the aforementioned regimen were found to be comparable to those of the previous regimen schedule, although further validation was deemed necessary¹³.

Relapse remains a challenge to achieving favorable long-term outcomes. In a study conducted by the Chinese APL Cooperative Group, the 2-year cumulative incidence of relapse (CIR) was 2.9% (2/69) in the ATRA-RIF group¹². Given the evidence that the combination of ATRA and arsenic shows synergy in eradicating leukemia cells in vitro and in vivo^{14,15}, we propose that a schedule of simultaneous administration of ATRA and arsenic may improve efficacy.

Consequently, we initiated a multicenter randomized trial APL16 to compare the efficacy and safety of RIF versus ATO during the consolidation phase in the simplified regimen. Here, we reported the results of the APL16 study to determine whether RIF is inferior to ATO in post-remission therapy.

Methods

Participants and eligibility

We recruited patients aged 14 to 75 years with newly diagnosed APL, classified as low to intermediate risk, from four independent medical centers in China. All participants provided written informed consent. This open-label study was approved by the Ethical Committee of the First Affiliated Hospital of Xi'an Jiaotong University in Xi'an, China (Approval No. XJTU1AF2016LSL-017).

Study design and regimen

Participants were randomly assigned (1:1) to two arms by using a computer-generated random sequence, stratified by age group and treatment institution. Per procedures in this research was in accordance with the Declaration of Helsinki.

Patients initially received ATRA when suspected of having APL, and ATO was administered after genetic confirmation. During the induction therapy, patients were admitted to the hospital to receive ATRA at a dose of 60 mg/d (20-45 mg/m²/d) plus ATO at 0.15 mg/kg/d until hematological complete remission (HCR). They were then randomized to receive either ATRA plus ATO or ATRA plus RIF (60mg/kg/d of the compound) as consolidation therapy. ATRA in combination with ATO/RIF was administered in cycles of 2 weeks on and 2 weeks off, with a total of 6 cycles after achieving molecular complete remission (MCR) (Figure 1). ATRA and RIF were administered orally in 3 divided doses per day. Patients in the ATRA-RIF group took oral medication at home and were followed up in an outpatient model during consolidation therapy. ATRA was administered at 20-45 mg/m² because previous studies¹⁶⁻¹⁸ have demonstrated that a lower dose of ATRA can achieve the same efficacy as the dose of 45 mg/m². A dosage of 60 mg/d of ATRA (equivalent to three pills per day) is a convenient option for patients.

All patients received standard supportive care, including prophylactic and therapeutic antibiotics and blood product transfusions. The treatment protocol details were previously published¹⁹ and also presented in the supplementary file.

Outcomes

The primary endpoint of this study was 2-year disease-free survival (DFS). Secondary endpoints included the incidence of adverse events and quality of life. Quality of life was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire²⁰.

Statistics

This multicenter randomized trial was designed with a noninferiority margin of -5%, a type I error of 5% (two-sided), and a power of 90%. Assuming 97% DFS in the ATRA-ATO group and 99% DFS in the ATRA-RIF group, we used PASS (version 11) to calculate a required sample size of 53 evaluable patients per group to draw a conclusion of non-inferiority.

The primary analyses were based on an intention-to-treat (ITT) population, which included patients who received at least one dose of the assigned treatment after randomization. Non-inferiority was evaluated by the difference in the 95% confidence interval between the two groups in 2-year DFS. We also performed per-protocol analysis for non-inferiority, which included patients who completed all treatments as planned. Baseline characteristics were summarized descriptively. The chi-squared test (χ^2) was used to compare the category variables. Survival distributions were estimated using the Kaplan-Meier method and were compared using the log-rank test (two-sided $\alpha = 5\%$). The significance level for all statistical tests was 0.05. Data were analyzed using SPSS Statistics, version 26.0, and Medcalc software, version 15.0.

Results

Patient characteristics

The enrolment of 114 patients started from September 19, 2016, to November 20, 2023. The analysis was completed in February 2024. Three patients who died within 72 hours were excluded: two due to intracranial hemorrhage and one due to acute myocardial infarction. Three of 111 patients were not evaluated for the following reasons: severe renal dysfunction in two patients and failure to provide informed consent in one patient. The ITT analysis included 108 patients who received at least one cycle of consolidation therapy. These patients were randomly assigned (1:1) to receive ATRA plus ATO or ATRA plus RIF. Two patients (5%) discontinued treatment in the consolidation phase due to poor compliance. Three

patients did not receive assigned treatment and crossed over to another group (Figure 2). The median follow-up time was 29 months (range, 2 to 88) and 62% (67/108) of patients were followed up for more than 2 years.

The final analyses included 56 males and 52 females with a median age of 40 years. The demographic and clinical characteristics of the two groups were not significantly different. Detailed information is illustrated in Table 1.

Response data

All 108 patients achieved HCR with a median time of 32 days and followed the consolidation therapy. The MCR rate reached 70% (76/108) after one cycle of consolidation. The MCR rate achieved 100% after four cycles of consolidation therapy. The median time to MCR was 2 months and 1.8 months in the ATRA-RIF and ATRA-ATO arms, respectively ($P= .41$) (Figure S1). The median number of cycles in the consolidation phase was 6.6 (range, 6 to 10), excluding patients with protocol violations.

The primary endpoint of the 2-year DFS was 97% in the ATRA-RIF group and 98% in the ATRA-ATO group in the ITT analysis ($P= 0.98$). The percentage difference in DFS was -1% (95%CI, -4.8 to 6.9), confirming the non-inferiority of the ATRA-RIF group based on a non-inferiority margin of -10% (Figure 3).

The per-protocol analysis included 47 patients in the ATRA-RIF group and 47 patients in the ATRA-ATO group who completed treatment as planned. The 2-year DFS was also 97% versus 98% in the ATRA-RIF group and ATRA-ATO group in the per-protocol analysis ($P= 0.99$). The percentage difference between the two groups was -1% (95%CI, -4.9 to 7.0), confirming non-inferiority.

Two patients experienced APL relapses, giving a cumulative relapse incidence of 2%. One patient in the ATRA-RIF group experienced a molecular relapse at 21 months after MCR, and then 71% of blasts were observed in his bone marrow aspirate 10 days later. He received salvage therapy of ATRA with ATO plus Venetoclax and achieved another MCR. However, he experienced a molecular relapse 4 months after the second MCR and prepared for an allogeneic bone marrow transplant. One patient in the ATRA-ATO group had CNS relapse one month after achieving MCR. Promyelocytic blasts were detected in the cerebrospinal fluid aspirate, but no promyeloblasts were found in the bone marrow. He received chemotherapy with 4 sequential intrathecal injections. He experienced MCR after 3 months of salvage therapy and remained in complete remission until the last follow-up in January 2024.

As of the end of the follow-up period, there have been no deaths or occurrences of secondary malignancies. The 2-year Overall survival rate was 100% in both groups. The median hospitalization days of patients in the ATRA-ATO group were 69 days. In contrast, patients in the ATRA-RIF group received consolidation therapy at home and completed disease monitoring under an outpatient model. They were able to continue working and maintain their functional and social well-being.

Adverse events and supportive care

In the induction phase, leukocytosis was developed in 61% (66/108) of patients with a median WBC count peak of $16.9 \times 10^9/L$ (range, 11.8-71.0), and the median time to peak was 6 (range, 3-17) days. A median total dosage of 24g of hydroxyurea was given to manage. As a consequence, 71% of patients who were given hydroxyurea experienced a transient elevation of blood uric acid level. Renal insufficiency was rare (5% assessed by blood creatinine level) through active supportive care. Differentiation syndrome occurred in 17 (16%) patients, which was all mild and successfully managed by dexamethasone and drug dose reduction.

Grade 3 to 4 disseminated intravascular coagulation was reported in 14 (14%) patients. Grade 3-4 neutropenia and thrombocytopenia that lasted for more than 14 days occurred in 12% (13/108) and 17% (18/108) patients, respectively.

Grade 3 to 4 non-hematological toxicity occurred relatively rarely except for infection. Grade 3-4 infection was reported in 19% (21/108) of patients. We gave intravenous antibiotics to 83% (90/105) of patients for preventive and curative aims with a median duration of 13 days. Major treatment-related adverse events during induction therapy are listed in Table S1.

The adverse event surveys during the consolidation therapy were available for 99 patients (Table 2). Most adverse events were grade 1 to 2. The most frequently reported adverse effect was hypertriglyceridemia (67% vs 56%, respectively; $P= 0.25$). The incidence of main adverse effects in the two groups did not differ. Diarrhea occurred in 18% of the ATRA-RIF group, which appeared to be more than the ATRA-ATO group, but the difference was not statistically significant (18% vs 6%, $P= 0.06$).

Discussion

We have verified that RIF is not inferior to ATO for post-remission therapy, even when using a simplified regimen with ATRA and arsenic given simultaneously. In our prior study APL15 and this study, we administered ATRA and arsenic agents on a 2-week on and 2-week off schedule to a total of 236 patients¹³. The simple regimen protocol yielded a CIR of 2.1% (5/236), which was comparable to previous studies^{12, 21, 22}.

ATRA and ATO target the RARA and PML moieties, respectively, to degrade the PML-RARA oncoprotein^{14, 23}. In addition, ATRA and ATO have synergistic anti-leukemia effects through different pathways^{24, 25}. This may be essential in eradicating PML-RARA-positive leukemic stem cells to make APL curable. Therefore, we administered ATRA and arsenic simultaneously instead of in separate cycles to maintain a constant plasma concentration during consolidation therapy. The co-administration of ATRA and ATO/RIF in a concurrent dosing regimen appears to be safe and may improve patient compliance, which is critical for home-based therapy. The results of our trial indicated that the median time to MCR was 2 and 1.8 months in the respective groups. This is shorter than the duration reported in previous studies, which may be attributed to the concurrent administration of the treatment^{7, 12}.

Despite the high cure rate, a minority of APL patients will relapse and the risk factor is still unclear. The CIR in this study was 2%. It is noteworthy that one patient who relapsed in the ATRA-RIF group experienced recurrent diarrhea during RIF treatment. Although diarrhea was readily managed, it could potentially affect the absorption of arsenic, leading to a reduction in plasma arsenic concentration²⁶. Inadequate plasma arsenic concentration has been suggested to be associated with relapse⁹. It is postulated that the plasma arsenic concentration may decrease due to diarrhea, although this was not directly tested. Another patient who relapsed experienced a headache during induction therapy and received a prophylactic intrathecal injection before achieving HCR. One month after HCR, APL blasts were later detected in the cerebrospinal fluid but not in the bone marrow. He achieved remission once more with intrathecal injections and ATRA plus ATO treatment. The safety and benefit of early prophylactic intrathecal injection before HCR remains uncertain.

Achieving minimal residual disease negativity is critical to avoid relapse^{27, 28}. A large cohort study has demonstrated that PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk APL. However, one study found that only 10% of patients achieved MCR after induction therapy²⁹. In previous studies^{1, 12}, patients received a fixed number of cycles of consolidation therapy following induction therapy. This suggests

that some patients may experience a shorter course of treatment following MCR. However, for those who achieve MCR later, a longer treatment may be necessary. All patients in the study received six cycles of post-remission therapy after MCR in order to achieve the best possible outcome.

The toxicity of RIF is a major concern. The results of our study indicate that RIF does not exhibit a significant increase in toxicity compared to ATO during consolidation therapy. Based on a chemotherapy-free consolidation therapy, the incidence of cardiotoxicity and hepatotoxicity was relatively lower than that reported in previous studies^{5, 22, 30}. No cases of grade 3-4 cardiotoxicity or hepatotoxicity were observed in this study. The frequency of QTc prolongation was less in the ATRA-RIF group than in the ATRA-ATO group, which may indicate a potential advantage of RIF. However, the difference was not statistically significant, and a larger sample size is still required to confirm this result. The incidence of diarrhea was 18% in the ATRA-RIF group, which is slightly higher than that reported in previous studies^{12, 31}. Further investigation is warranted to assess the impact of diarrhea on the absorption and efficacy of RIF.

Although a convenient oral regimen was employed for consolidation, it was not extended to induction therapy due to the higher WBC count peak observed in the RIF group in previous studies³². A limitation of this study is the absence of a direct comparison between the 2-week on and 2-week off regimen and a conventional regimen. However, the relapse rate in both groups was comparable to that observed in previous studies. A historical cohort comparison will be performed later to provide further validation. The secondary endpoint of the study was the quality of life. To our knowledge, no prospective study has reported differences in patient quality of life between RIF and ATO. We will report quality-of-life outcomes and the long-term prognosis of the APL16 trial later. In conclusion, the results of this multicenter randomized trial APL16 confirmed that oral RIF is not inferior to intravenous ATO for APL in a simplified protocol. This study proposes the simplest home-based treatment manner with RIF. Our study will inspire subsequent studies to simplify treatment and improve the treatment experience for APL patients.

References

1. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med*. 2013;369(2):111-121.
2. Cicconi L, Platzbecker U, Avvisati G, et al. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. *Leukemia*. 2020;34(3):914-918.
3. Jiang H, Liang GW, Huang XJ, et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. *Leuk Res*. 2015;39(12):1319-1324.
4. Chen SJ, Zhou GB, Zhang XW, Mao JH, de Thé H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. *Blood*. 2011;117(24):6425-6437.
5. Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. *J Clin Oncol*. 2013;31(33):4215-4221.
6. Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. *Proc Natl Acad Sci U S A*. 2008;105(12):4826-4831.
7. Zhu HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. *N Engl J Med*. 2014;371(23):2239-2241.
8. Huang SL, Guo AX, Xiang Y, et al. Clinical study of the compound Qingdai tablets for the treatment of acute promyelocytic leukemia. *Zhonghua Xue Ye Xue Za Zhi*. 1995;16(1):26-28.
9. Huang DP, Yang LC, Chen YQ, et al. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group. *Blood Cancer J*. 2023;13(1):178.
10. Au WY, Kumana CR, Lee HK, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. *Blood*. 2011;118(25):6535-6543.
11. Zhu HH, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. *Blood*. 2019;134(7):597-605.
12. Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. *Lancet Oncol*. 2018;19(7):871-879.
13. Wang HY, Gong S, Li GH, et al. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). *Blood Cancer J*. 2022;12(11):158.
14. Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thé H. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. *Nat Med*. 2014;20(2):167-174.
15. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. *J Exp Med*. 1999;189(7):1043-1052.
16. Castaigne S, Lefebvre P, Chomienne C, et al. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m²) in acute promyelocytic leukemia. *Blood*. 1993;82(12):3560-3563.
17. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. *Leukemia*. 1996;10(5):825-828.
18. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As₂O₃ combination yields

a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. *Proc Natl Acad Sci U S A*. 2004;101(15):5328-5335.

19. Zhang X, Liu L, Yao Y, et al. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA): study protocol for a randomized controlled trial. *Trials*. 2020;21(1):7.

20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst*. 1993;85(5):365-376.

21. Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2015;16(13):1295-1305.

22. Zheng H, Jiang H, Hu S, et al. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. *J Clin Oncol*. 2021;39(28):3161-3170.

23. de Thé H, Pandolfi PP, Chen Z. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. *Cancer Cell*. 2017;32(5):552-560.

24. Tarkanyi I, Dudognon C, Hillion J, et al. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. *Leukemia*. 2005;19(10):1806-1811.

25. Zheng PZ, Wang KK, Zhang QY, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. *Proc Natl Acad Sci U S A*. 2005;102(21):7653-7658.

26. Jiang Z, Sun Y, Wu Z, et al. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology. *J Ethnopharmacol*. 2023;317:116895.

27. Huang W, Sun GL, Li XS, et al. Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. *Blood*. 1993;82(4):1264-1269.

28. Laczika K, Mitterbauer G, Korninger L, et al. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. *Leukemia*. 1994;8(1):1-5.

29. Tang FF, Lu SY, Zhao XS, et al. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. *Br J Haematol*. 2021;195(5):722-730.

30. Yang MH, Wan WQ, Luo JS, et al. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. *Am J Hematol*. 2018;93(12):1467-1473.

31. Ma YF, Lu Y, Wu Q, et al. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia. *J Hematol Oncol*. 2022;15(1):148.

32. Wang F, Jia JS, Wang J, et al. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia. *Leuk Res*. 2017;61:84-88.

Table 1. Baseline Characteristics

Characteristics(N=108)	ATRA-RIF(N=54)	ATRA-ATO(N=54)
Age, y		
median(range)	38(16-73)	41(14-74)
Sex, N (%)		
female	29(53.7)	23(42.6)
male	25(46.3)	31(57.4)
Sanz risk, N (%)		
intermediate-risk	34(63.0)	37(68.5)
low-risk	20(37.0)	17(31.5)
WBC count, $\times 10^9/L$		
median(range)	1.4(0.4-9.5)	1.7(0.3-8.6)
Platelet count, $\times 10^9/L$		
median(range)	33(2-165)	21(2-143)
FLT3-ITD mutation, N (%)		
FLT3-ITD positive	8(14.8)	9(16.7)
FLT3-ITD negative	36(66.7)	39(72.2)
Unknown*	10(18.5)	6(11.1)
PML-RAR α breakpoint [†] , N (%)		
L	29(53.7)	31(57.4)
S	17(31.5)	18(33.3)
V	6(11.1)	3(4.5)
Unknown*	2(3.7)	2(2.0)

*Sixteen patients did not detect the FLT3-ITD mutation and 4 patients did not detect the type of PML-RARA breakpoint of bone marrow for financial reason.

[†]The PML-RAR α breakpoint includes the long (L), variant (V), and short (S) isoforms.

Abbreviations: WBC, White blood cell.

Table 2. Incidence of main adverse events during consolidation therapy

	ATRA-RIF (N=49)		ATRA-ATO (N=49)		<i>P</i>
	Grade1-2	Grade3-4	Grade1-2	Grade3-4	
Anemia	10 (20.4)	0	15 (30.6)	1 (2.0)	-
Hemorrhage/thrombosis	3 (6.1)	0	4 (8.1)	0	-
Increased AST or ALT	7 (14.3)	0	9 (18.4)	0	-
Hypertriglyceridemia	25 (51.0)	5 (10.2)	28 (57.1)	2 (4.1)	.44
Nausea	16 (32.7)	1 (2.0)	18 (36.7)	0	-
Vomit	10 (20.4)	0	8 (16.3)	0	-
Diarrhea	9 (18.4)	0	3 (6.1)	0	-
Rash	8 (16.3)	0	7 (14.3)	0	-
Headache	14 (28.6)	1 (2.0)	11 (22.4)	0	-
Dry skin or mouth	7 (14.3)	0	9 (18.4)	0	-
Tinnitus	3 (6.1)	0	3 (6.1)	0	-
Prolonged QTc	2 (4.1)	0	4 (8.2)	0	-
Heart failure	3 (6.1)	0	4 (8.2)	0	-
Insomnia	6 (12.2)	0	8 (16.3)	0	-

Data are expressed as n (%). Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; QTc, the Corrected QT Interval.


Figure Legends

Figure 1. **Treatment regimen.** ATRA, all-trans retinoic acid. RIF, Realgar-*Indigo naturalis* formula. HCR, hematological complete remission. MCR, molecular complete remission. ★ indicates one or several repeated cycles of treatment until achieving MCR (1-3 cycles in this trial).

Figure 2. **CONSORT diagram.** ITT, intention-to-treat.

Figure 3. **Disease-free survival in ITT analysis.** * Disease-free survival curves in the PP analysis are not shown because the cases censored in the PP and ITT analyses were consistent.

Figure 1







Figure 3



No. at risk

Months

ATRA-ATO

54

44

34

19

13

ATRA-RIF

54

45

32

22

14

SUPPLEMENTARY FILE

TABLE OF CONTENTS

Supplements of methods.....	page 1
Tables S1.....	page 2
Tables S2.....	page 3
Figure S1.....	page 4
Extended Table 2.....	page 5

Supplements of methods

Institutions participating in APL16 study included: The First Affiliated Hospital of Xi'an Jiaotong University, Tang-Du Fourth Military Medical University of Chinese PLA, Baoji People's Hospital, and Xi'an Gaoxin Hospital.

Inclusion criteria

- Age 14–75 years
- Newly diagnosed APL. (The genetic diagnosis was based on the presence of the t(15;17) or PML-RARA fusion genes.)
- Pre-treatment peripheral blood white blood cell (WBC) count $< 10 \times 10^9 /L$
- Signed written informed consent provided by the patient or their family

Exclusion criteria

Exclusion criteria for this study included drug allergy, cardiac insufficiency (left ventricular ejection fraction less than 50%), inadequate renal reserve (creatinine greater than 3 times the upper limit of normal), significant arrhythmias or electrocardiogram abnormalities, other malignant tumors combined, pregnancy and lactation.

Supportive care and monitoring

Dexamethasone at a dosage of 10 mg every 12 hours was intravenously administered to patients suspected of having differentiation syndrome until signs and symptoms disappeared.

Patients with leukocytosis (defined as a peripheral WBC count greater than $10 \times 10^9/L$) were given 1g of hydroxyurea four times daily. No anthracycline or homoharringtonine was used to manage leukocytosis.

Patients with CNS leukemia require routine intrathecal therapy. No prophylaxis of CNS leukemia was regularly performed.

Dose adjustments or discontinuation of ATRA and ATO/RIF were implemented for patients who experienced grade 3 to 4 drug-related toxicity or differentiation syndrome.

Bone marrow aspirates were taken the day before the next treatment cycle to monitor PML-RARA expression during the consolidation therapy. We monitor bone marrow samples every 3 months after finishing the consolidation therapy. The observation lasted for 2 years.

Definition of Outcomes

Disease-free survival (DFS) is defined from enrolment to the time of any form of relapse or death.

Overall survival (OS) is defined from enrolment to the time of death due to any cause.

Adverse events were assessed using the Common Terminology Criteria for Adverse Events of the US National Cancer Institute, version 4. Adverse events during the induction therapy were divided into hematological and non-hematological.

Quality of life questionnaires were collected at 2 weeks after the end of induction therapy and at the end of the 3rd cycle of consolidation therapy.

Table S1. Incidence of hematologic and nonhematologic toxicity during induction therapy

	Total	Grade1	Grade2	Grade3	Grade4
Hematological toxicity					
neutropenia	100(92.6)	8(7.4)	12(11.1)	34(31.5)	46(42.6)
thrombocytopenia	102(94.4)	1(0.9)	7(6.5)	23(21.3)	71(65.7)
anemia	104(96.3)	9(8.3)	6(5.6)	51(47.2)	38(35.2)
leukocytosis	66(61.1)	-	-	61(56.5)	5(4.6)
DIC	34(31.5)	-	20(18.5)	11(10.2)	3(2.8)
hemorrhage	25(23.1)	17(15.7)	8(7.4)	0	0
Non-hematological toxicity					
increased AST or ALT	66(61.1)	47(43.5)	14(13.0)	5(4.6)	0
increased creatinine	5(4.6)	4(3.7)	1(0.9)	0	0
heart failure	9(8.3)	3(2.8)	4(3.7)	2(1.8)	0
infection	62(57.4)	12(11.1)	29(26.9)	16(14.8)	5(4.6)
prolonged QTc	13(12.0)	9(8.3)	3(2.8)	0	1(0.9)
nausea	24(22.2)	7(6.5)	15(13.9)	2(1.9)	0
vomit	12(11.1)	10(9.3)	2(1.9)	0	0
diarrhea	7(6.5)	4(3.7)	3(2.8)	0	0
mucositis	14(13.0)	8(7.4)	5(4.6)	1(0.9)	0
headache	9(8.3)	5(4.6)	4(3.7)	0	0

Data are expressed as n (%). Abbreviations: DIC, disseminated intravascular coagulation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; QTc, the Corrected QT Interval.

Table S2. Plasma and urine arsenic concentrations measured in six patients in the ATRA-RIF group.

ID	group	Date of test	Point of consolidation	Plasma arsenic concentrations (µg/L)	Urine arsenic concentrations (µg/L)
1	ATRA-RIF	2017/7/16	6 th cycle	75	1839
2	ATRA-RIF	2017/11/21	1 st cycle	19	235
2	ATRA-RIF	2018/5/10	6 th cycle	98	1737
3	ATRA-RIF	2018/1/4	1 st cycle	79	896
3	ATRA-RIF	2018/7/1	6 th cycle	61	650
4	ATRA-RIF	2018/1/17	1 st cycle	76	1987
4	ATRA-RIF	2018/6/30	6 th cycle	38	1368
5	ATRA-RIF	2018/5/10	2 nd cycle	143	2181
5	ATRA-RIF	2018/9/22	6 th cycle	19	174
6	ATRA-RIF	2018/9/20	5 th cycle	58	591
6	ATRA-RIF	2018/10/19	6 th cycle	39	1608

(Six patients, including three males and three females, in the ATRA-RIF group were randomized to blood and urine arsenic concentrations during the consolidation therapy. The blood and urine specimens were collected on the same day for each test.)




Figure S1. The cumulative incidence of molecular complete remission

Extended Table2. Incidence of Grade1-2 adverse events during consolidation therapy

	ATRA-RIF(N=49)	ATRA-ATO(N=49)	<i>P</i>
	Grade 1-2	Grade 1-2	Grade 1-2
Anemia	10 (20.4, 9.1-31.7)	15(30.6, 17.7-43.5)	.25
Hemorrhage/thrombosis	3 (6.1, 0-12.8)	4(8.1, 8.2-15.8)	1.0
Increased AST or ALT	7(14.3, 4.5-24.1)	9(18.4, 7.5-29.2)	.59
Hypertriglyceridemia	25(51.0, 37.0-65.0)	28(57.1, 37.6-76.6)	.69
Nausea	16(32.7, 16.7-49.5)	18(36.7, 20.0-53.8)	.67
Vomit	10(20.4, 9.1-31.7)	8(16.3, 6.0-26.7)	.60
Diarrhea	9(18.4, 7.5-29.2)	3(6.1, 0-12.8)	.06
Rash	8(16.3, 6.0-26.7)	7(14.3, 4.5-24.1)	.78
Headache	14(28.6, 15.9-41.2)	11(22.4, 10.8-34.1)	.49
Dry skin or mouth	7(14.3, 4.5-24.1)	9(18.4, 7.5-29.2)	.59
Tinnitus	3(6.1, 0-12.8)	3(6.1, 0-12.8)	-
Prolonged QTc	2(4.1, 0-9.6)	4(8.2, 8.2-15.8)	.67
Heart failure	3(6.1, 0-12.8)	4(8.2, 8.2-15.8)	1.0
Insomnia	6(12.2, 3.1-21.4)	8(16.3, 6.0-26.7)	.56

Data are expressed as n (% , 95% CI of the incidence).

Incidence of Grade 3-4 adverse events during consolidation therapy

	ATRA-RIF(N=49)	ATRA-ATO(N=49)	<i>P</i>
	Grade 3-4	Grade 3-4	Grade 3-4
Anemia	0	1(2.0, 0-6.0)	-
Hemorrhage/thrombosis	0	0	-
Increased AST or ALT	0	0	-
Hypertriglyceridemia	5(10.2, 1.7-18.7)	2(4.1, 0-9.6)	.44
Nausea	1(2.0, 0-6.0)	0	-
Vomit	0	0	-
Diarrhea	0	0	-
Rash	0	0	-
Headache	1(2.0, 0-6.0)	0	-
Dry skin or mouth	0	0	-
Tinnitus	0	0	-
Prolonged QTc	0	0	-
Heart failure	0	0	-
Insomnia	0	0	-

Data are expressed as n (% , 95% CI of the incidence).